QQQ   426.41 (-1.09%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   426.41 (-1.09%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   426.41 (-1.09%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   426.41 (-1.09%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)

GSK (GSK) Stock Forecast & Price Target

$39.95
-0.55 (-1.36%)
(As of 04/16/2024 ET)

GSK Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 5 Analyst Ratings

Analysts' Consensus Price Target

N/A

TypeCurrent Forecast
4/18/23 to 4/17/24
1 Month Ago
3/19/23 to 3/18/24
3 Months Ago
1/18/23 to 1/18/24
1 Year Ago
4/18/22 to 4/18/23
Consensus Rating
Hold
Hold
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
3 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Predicted UpsideN/AN/AN/AN/A
Get GSK Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

GSK Stock vs. The Competition

TypeGSKMedical CompaniesS&P 500
Consensus Rating Score
2.40
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside938.66% Upside12.13% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/4/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy
2/13/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy
1/23/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageEqual Weight
1/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageReduce

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 12:54 PM ET.

GSK Price Target - Frequently Asked Questions

What is GSK's consensus rating?

According to the issued ratings of 5 analysts in the last year, the consensus rating for GSK stock is Hold based on the current 1 sell rating, 1 hold rating and 3 buy ratings for GSKthe . Learn more on GSK's analyst rating history.

Do Wall Street analysts like GSK more than its competitors?

Analysts like GSK less than other Medical companies. The consensus rating for GSK is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how GSK compares to other companies.

Is GSK being upgraded by Wall Street analysts?

Over the previous 90 days, GSK's stock had 2 upgrades by analysts.

What analysts cover GSK?

GSK has been rated by Citigroup, Guggenheim, and Morgan Stanley in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:GSK) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners